These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16682709)

  • 41. Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction.
    Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Wienbergen H; Zahn R; Senges J
    Thromb Haemost; 2008 Jan; 99(1):150-4. PubMed ID: 18217147
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial.
    Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators
    Lancet; 2006 Feb; 367(9510):569-78. PubMed ID: 16488800
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial.
    Giugliano RP; Roe MT; Harrington RA; Gibson CM; Zeymer U; Van de Werf F; Baran KW; Hobbach HP; Woodlief LH; Hannan KL; Greenberg S; Miller J; Kitt MM; Strony J; McCabe CH; Braunwald E; Califf RM;
    J Am Coll Cardiol; 2003 Apr; 41(8):1251-60. PubMed ID: 12706917
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis.
    Murphy SA; Gibson CM; Morrow DA; Van de Werf F; Menown IB; Goodman SG; Mahaffey KW; Cohen M; McCabe CH; Antman EM; Braunwald E
    Eur Heart J; 2007 Sep; 28(17):2077-86. PubMed ID: 17600038
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis.
    Gabriel RS; White HD
    Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):851-7. PubMed ID: 17867915
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy.
    Goodman SG; Bozovich GE; Tan M; Dos Santos A; Gurfinkel EP; Cohen M; Langer A;
    Am Heart J; 2006 Apr; 151(4):791-7. PubMed ID: 16569535
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage.
    Giugliano RP; McCabe CH; Antman EM; Cannon CP; Van de Werf F; Wilcox RG; Braunwald E;
    Am Heart J; 2001 May; 141(5):742-50. PubMed ID: 11320361
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    Am J Cardiol; 1998 Sep; 82(5B):19L-24L. PubMed ID: 9737476
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II).
    Ross AM; Molhoek P; Lundergan C; Knudtson M; Draoui Y; Regalado L; Le Louer V; Bigonzi F; Schwartz W; de Jong E; Coyne K;
    Circulation; 2001 Aug; 104(6):648-52. PubMed ID: 11489769
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes.
    Cohen M; Mahaffey KW; Pieper K; Pollack CV; Antman EM; Hoekstra J; Goodman SG; Langer A; Col JJ; White HD; Califf RM; Ferguson JJ;
    J Am Coll Cardiol; 2006 Oct; 48(7):1346-54. PubMed ID: 17010793
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prehospital administration of tenecteplase for ST-segment elevation myocardial infarction in a rural EMS system.
    Crowder JS; Hubble MW; Gandhi S; McGinnis H; Zelman S; Bozeman W; Winslow J
    Prehosp Emerg Care; 2011; 15(4):499-505. PubMed ID: 21815730
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
    Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis.
    Gibson CM; Pride YB; Aylward PE; Col JJ; Goodman SG; Gulba D; Bergovec M; Kunadian V; Zorkun C; Buros JL; Murphy SA; Antman EM
    J Thromb Thrombolysis; 2009 Jan; 27(1):11-7. PubMed ID: 18695943
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
    Antman EM; Cohen M; Bernink PJ; McCabe CH; Horacek T; Papuchis G; Mautner B; Corbalan R; Radley D; Braunwald E
    JAMA; 2000 Aug; 284(7):835-42. PubMed ID: 10938172
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time.
    Bozovich GE; Gurfinkel EP; Antman EM; McCabe CH; Mautner B
    Am Heart J; 2000 Oct; 140(4):637-42. PubMed ID: 11011339
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis.
    Giraldez RR; Nicolau JC; Corbalan R; Gurfinkel EP; Juarez U; Lopez-Sendon J; Parkhomenko A; Molhoek P; Mohanavelu S; Morrow DA; Antman EM
    Eur Heart J; 2007 Jul; 28(13):1566-73. PubMed ID: 17562672
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events).
    Montalescot G; Ellis SG; de Belder MA; Janssens L; Katz O; Pluta W; Ecollan P; Tendera M; van Boven AJ; Widimsky P; Andersen HR; Betriu A; Armstrong P; Brodie BR; Herrmann HC; Neumann FJ; Effron MB; Lu J; Barnathan ES; Topol EJ;
    JACC Cardiovasc Interv; 2010 Feb; 3(2):203-12. PubMed ID: 20170878
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
    Antman EM; McCabe CH; Gurfinkel EP; Turpie AG; Bernink PJ; Salein D; Bayes De Luna A; Fox K; Lablanche JM; Radley D; Premmereur J; Braunwald E
    Circulation; 1999 Oct; 100(15):1593-601. PubMed ID: 10517729
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial.
    Cohen M; Gensini GF; Maritz F; Gurfinkel EP; Huber K; Timerman A; Krzeminska-Pakula M; Santopinto J; Hecquet C; Vittori L;
    Circulation; 2003 Oct; 108(16 Suppl 1):III14-21. PubMed ID: 14605015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.